Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase DeficiencyGlobeNewsWire • 08/17/21
Amazon, Mastercard, Pinterest and More Friday Afternoon Analyst Upgrades and Downgrades24/7 Wall Street • 07/30/21
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/30/21
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 07/29/21
Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021GlobeNewsWire • 07/15/21
Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase DeficiencyGlobeNewsWire • 06/28/21
Agios Launches myAgios® Patient Support Services for Pyruvate Kinase DeficiencyGlobeNewsWire • 06/22/21
Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase DeficiencyGlobeNewsWire • 06/21/21
Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual CongressGlobeNewsWire • 06/11/21
Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual CongressGlobeNewsWire • 06/11/21
Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual CongressGlobeNewsWire • 05/12/21
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/29/21
Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021GlobeNewsWire • 04/15/21